Investment Rating - The report does not explicitly provide an investment rating for the industry. Core Insights - The report highlights significant advancements in the pharmaceutical industry, particularly in the development and approval of innovative drugs, with a focus on oncology and immunotherapy [5][6][10]. Summary by Sections 1. Latest Policy Updates - The National Medical Products Administration (NMPA) has issued several key announcements, including guidelines to strengthen the supervision of entrusted drug production and the release of the 2025 Clinical Application Guidelines for Antitumor Drugs [10][15][18]. - New regulations aim to support the development of innovative drugs and ensure the quality and safety of pharmaceuticals through enhanced management practices [11][12][14]. 2. Domestic New Drug Approvals - In January 2026, a total of 172 new drugs were approved for clinical trials, a decrease of 55 from the previous month. Among these, 78 were chemical drugs, 88 were biological products, and 6 were traditional Chinese medicines [22][23]. - The majority of new drug approvals were in the fields of oncology and immune modulation, accounting for 53% of the total [22]. 3. Global Innovative Drug Development - The report lists several drugs that have shown positive clinical results, including Neumora Therapeutics' NMRA-511 and GSK's new hepatitis B drug, which achieved success in phase 3 studies [6][10]. - Notable approvals include the BCL-2 inhibitor from BeiGene, which received dual indications for chronic lymphocytic leukemia and mantle cell lymphoma [40][41]. 4. New Drug Listings - The report details new drug listings, including the approval of the combination drug for ADHD treatment by Aikobai, which has shown significant efficacy in clinical trials [41][43]. - The approval of Merck's drug for pulmonary arterial hypertension represents a new treatment option that addresses the underlying causes of the disease rather than just symptomatic relief [40].

Core Viewpoint - The major shareholder of Qianyuan Pharmaceutical, Zhao Qun, has had 15.78 million shares frozen by the court, representing 100% of his holdings and 6.16% of the company's total shares, due to a pre-litigation preservation request [1][2]. Group 1: Shareholder and Legal Issues - Zhao Qun's shares were frozen due to a court ruling related to a claim made by Cao Xitong, with the frozen amount set at 50 million yuan [1]. - The company clarified that the legal issues involving Zhao Qun are unrelated to the company and do not stem from any overdue debts or violations that could harm the company's interests [2]. Group 2: Company Performance - Qianyuan Pharmaceutical reported a significant decline in net profit for the first half of 2025, with a notable increase in revenue in the third quarter, achieving 238 million yuan, a 14.82% year-on-year growth, and a net profit of approximately 21.95 million yuan, up 106.06% [3]. - Despite the strong quarterly performance, the cumulative results for the first three quarters of 2025 showed a slight revenue increase of 0.44% to 611 million yuan, but a significant drop in net profit by 49.43% to about 22.33 million yuan [3][4]. - Financial expenses have increased by 50.80% year-on-year, reaching approximately 17.52 million yuan, primarily due to rising bank loan interest [4]. Group 3: Market Information - As of February 10, Qianyuan Pharmaceutical's stock closed at 12.00 yuan per share, with a total market capitalization of approximately 3.073 billion yuan [5].

Financial Data and Key Metrics Changes - In Q4 2025, total revenues reached $1.51 billion, a 28% increase year-over-year, while full-year revenues totaled $5.14 billion, up 21% from the previous year [4][29] - Net sales for Q4 were $1.22 billion, representing a 20% increase compared to the prior year, with full-year net sales at $4.35 billion, also up 20% year-over-year [5][29] - R&D expenses for Q4 were $611 million, a 31% increase from the prior year, with full-year R&D expenses at $2.05 billion [29][30] - SG&A expenses for Q4 were $390 million, increasing 19% year-over-year, with full-year SG&A expenses at $1.38 billion, up 11% [29][30] Business Line Data and Key Metrics Changes - Core business sales excluding Jakafi totaled $1.26 billion, a 53% increase from 2024, with expectations for over 30% growth in 2026 [5][12] - Jakafi sales in Q4 were $828 million, an increase of 7% year-over-year, with full-year sales at $3.093 billion, representing an 11% increase [6][29] - Opzelura's Q4 net sales were $207 million, up 28%, with full-year sales at $678 million, a 33% increase [9][29] - Hematology and oncology product sales in Q4 were $187 million, up 121% year-over-year, with full-year sales at $583 million, an 83% increase [10][29] Market Data and Key Metrics Changes - The pediatric launch of Opzelura for atopic dermatitis is performing well, with annualized sales around $30 million [9] - International sales for Opzelura in vitiligo doubled to $130 million in 2025 [9] - The hematology and oncology business is expected to generate $800-$880 million in 2026, representing a 40%-50% increase compared to 2025 [12][29] Company Strategy and Development Direction - The company aims to transition its core business and pipeline, with multiple assets moving from early to late-stage development [3][4] - The focus is on expanding the core business, with expectations for product launches in late 2026 and early 2027 [12][14] - The company views business development as a multiplier to strengthen its core, with a focus on strategic fit and potential for durable revenue [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, with a revenue guidance for 2026 set at $4.77 billion-$4.94 billion, a 10%-13% increase from the prior year [31][32] - The company anticipates a significant increase in core business growth, with expectations for Jakafi sales to be between $3.22 billion and $3.27 billion in 2026 [31] - Management emphasized the importance of execution in orchestrating product launches and managing multiple phase three trials [32] Other Important Information - The company has submitted regulatory applications for Jakafi XR, Opzelura, and povorcitinib in Europe [4] - The pipeline has reached a new level of maturity, with 14 pivotal trials expected to be underway by the end of 2026 [15][16] Q&A Session Summary Question: Thoughts on CALR pivotal programs and dosing strategies - Management indicated that they will discuss dosing strategies with the FDA and are confident in their approach [36][39] Question: Opzelura uptake and average usage - Management noted that the AD business is growing at nearly 20% year-over-year, with significant growth expected in the pediatric segment [42][45] Question: Monjuvi's opportunity in front-line DLBCL - Management highlighted that Monjuvi is positioned as an addition to R-CHOP, with a competitive PFS benefit [47][51] Question: Opzelura in PN and FDA recommendations - Management clarified that the FDA recommended an additional trial for Opzelura in PN due to mixed results from previous studies, with no implications for HS [59][62] Question: mCALR bispecific and V617F program - Management expressed confidence in the mCALR bispecific program and the potential of the V617F program to deliver transformative clinical effects [64][68]

庆阳市侨联作为联系侨界与地方的桥梁，近年来积极协调爱心资源，对接基层实际需求，助力包括步长 制药在内的多家企业在当地开展公益项目。此次致信，既是对步长制药公益行为的肯定，也体现了侨联 服务地方、汇聚侨力的工作职能。 步长制药有关负责人表示，企业将继续秉持服务社会的理念，结合庆阳的实际需要，在健康帮扶方面探 索更多可持续的模式。庆阳市侨联有关负责人也表示，将进一步做好联络服务工作，促进公益资源与地 方发展需求精准对接。 中证报中证网讯（记者 张鹏飞）近日，庆阳市归国华侨联合会向步长制药子公司陕西步长制药有限公 司（简称"陕西步长"）致送感谢信，代表全市侨界和受助群众对该企业长期以来的公益支持表示诚挚感 谢。 感谢信中提到，步长制药多年来持续关注庆阳革命老区医疗卫生事业发展，结合自身行业优势，通过捐 赠急需药品、协助提升医疗设备水平、开展健康帮扶等方式，为当地医疗条件改善提供了切实帮助。相 关物资对基层医疗资源起到了有效补充的作用，使群众能够更方便地获得医疗服务。 转自：中国证券报·中证网 ...

证券日报网讯 2月10日，红日药业在互动平台回答投资者提问时表示，根据信息披露的公平性与合规性 要求，互动易平台并非法定信息披露渠道，公司不会通过此渠道代替正式公告或泄露未公开重大信息。 对于达到披露标准的事项，公司将严格依法依规及时履行信息披露义务。所有公开信息均以公司在指定 媒体发布的定期报告和公告为准。 （文章来源：证券日报） ...

Group 1 - The core point of the article is that Xuantai Pharmaceutical announced its participation in the national organized procurement for drugs whose agreements have expired, specifically regarding the procurement of ursodeoxycholic acid capsules [2] - The company received notification from the procurement office on February 10, 2026, indicating that its product is proposed to be selected in the continuation of the procurement process [2]

Incyte周二公布的年度销售额预期低于华尔街预估，其主要增长动力Opzelura药物预计表现不佳，这加 剧了外界对这家制药商能否抵消其最畅销药物Jakafi即将到来的专利到期影响的担忧。 这家总部位于特拉华州威尔明顿的公司，股价在盘前交易中下跌超过4%。 公司预计Opzelura在2026年实现营收7.5亿至7.9亿美元，低于分析师预估的8.015亿美元。 尽管第四季度表现强劲——Opzelura销售额大涨28%至2.073亿美元，高于预期的1.956亿美元——但公司 仍给出了谨慎展望。 蒙特利尔银行（BMO）分析师Evan Seigerman表示："Opzelura的预期偏弱，意味着2026年仍有不少工作 要做。"投资者正密切关注，在Jakafi专利到期后，这款增长型药物能否填补收入缺口。 Opzelura用于治疗12岁及以上患者的白癜风和特应性皮炎。公司预计今年下半年将获得监管审批结果， 计划2026年底在美国以外市场推出其中重度特应性皮炎适应症。 Jakafi是Incyte用于治疗骨髓纤维化、真性红细胞增多症等血液癌症的旗舰药物，目前仍是公司最畅销产 品。Incyte预计2026年Jakafi销售额为 ...

Financial Data and Key Metrics Changes - Total revenue increased by 8% in 2025, with product revenue growing by 10% driven by global demand for innovative medicines [7][18] - Core EPS grew by 11%, aligning with full-year guidance [18] - Operating profit increased by 9%, with a focus on operating leverage [20] - Cash flow from operating activities rose by 23% to $14.6 billion [21] - Core gross margin landed at 82%, consistent with expectations [18] Business Line Data and Key Metrics Changes - Oncology revenues reached $25.6 billion, up 14% year-over-year, with Tagrisso, Imfinzi, and Calquence showing significant growth [26][27] - BioPharmaceuticals revenue increased by 5% to $23 billion, with growth medicines outpacing the impact of generic entries [40] - Rare Disease revenue grew by 4% to $9.1 billion, driven by neurology indications and increased patient demand [52] Market Data and Key Metrics Changes - U.S. market saw a 10% growth, while emerging markets outside of China experienced a 22% increase [11] - Europe grew by 7%, and China grew by 4% despite losing Pulmicort to generics [11] - Alliance revenue surged by 38%, reflecting increased contributions from partnered products [18] Company Strategy and Development Direction - The company aims to reach $80 billion in revenue by 2030, with a focus on expanding its pipeline and diversifying its product offerings [7][13] - Significant investments are being made in R&D, particularly in areas like ADCs, cell therapy, and bispecifics [24][50] - The company is prioritizing technologies that will shape the future of medicine, including weight management and cardiovascular treatments [14][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining growth despite known headwinds, including patent expirations and market competition [22][23] - The company anticipates continued strong performance in 2026, with core EPS growth projected in the low double digits [22][25] - Management highlighted the importance of a diversified pipeline to mitigate risks associated with product concentration [10] Other Important Information - The company confirmed a second interim dividend of $2.17 per share, with plans to increase the annual declared dividend to $3.30 in 2026 [22] - The company has over 100 ongoing phase III trials, with significant revenue potential from upcoming readouts [12][59] - Management acknowledged the contributions of outgoing head of investor relations, Andy Barnett, and welcomed his successor, Joris [60][61] Q&A Session Summary Question: What are the expectations for growth in the oncology segment? - The oncology segment is expected to continue its strong momentum, with several key approvals and product launches anticipated in 2026 [30][31] Question: How is the company addressing the challenges posed by generic competition? - The company is focusing on expanding its product portfolio and enhancing its R&D efforts to mitigate the impact of generics [40][44] Question: What are the key catalysts for growth in the rare disease segment? - Key catalysts include the anticipated readouts for Ultomiris and Strensiq, as well as ongoing market expansion efforts [52][56]

本报讯 （记者王镜茹）2月10日，广州医药集团有限公司（以下简称"广药集团"）正式揭牌成立广州医药数智科技有限公 司（以下简称"广药数科公司"）与广州广药产业运营管理有限公司（以下简称"广药产业运营管理公司"）。 这两家专业化平台公司的成立，标志着广药集团在深化国企改革、优化资源配置、加快数字化转型方面迈出新的实质性步 伐，为广药集团深入推进"现代化、科技化、数字化、国际化"发展路径注入新动能。 同日揭牌的广药产业运营管理公司作为广药集团旗下专业的资产管理与工程代建平台，旨在以专业化运营、市场化运作的 核心理念，统筹盘活存量资产、高效推进工程项目建设、科学处置"两非"（非主业、非优势）业务，推动资产管理进入系统整 合、价值提升、成本优化的新阶段。 据介绍，该公司将构建"一本账、一张图、一个平台"的动态管理体系，系统推进资产盘活、历史遗留问题化解与安全隐患 整治，不仅将全面统筹广药集团分布于全国的存量资源，还将实现对广药集团重大建设项目的集中化、专业化管理。 据悉，广药数科公司将以"AI引领、市场导向、立足广药、服务行业"为总目标，重点围绕医药行业数字化解决方案、 AI+医药研发两大核心领域，聚焦网络信息安全、 ...

Core Viewpoint - Zhejiang Chengyi Pharmaceutical Co., Ltd. announced participation in the national organized procurement for the first to eighth batches, with four products proposed for selection, covering a procurement period until December 31, 2028 [1] Group 1: Procurement Details - The four products proposed for selection are Glucosamine Hydrochloride Capsules, Torasemide Injection, Lidocaine Hydrochloride Injection, and L-Carnitine Injection [1] - The procurement is organized by a coalition of provinces and the Xinjiang Production and Construction Corps, with Jiangsu, Henan, and Guangdong provinces leading the unified national procurement [1] - Selected drugs will be prioritized for use by medical institutions, ensuring the completion of the agreed procurement volume [1] Group 2: Financial Impact - Glucosamine Hydrochloride Capsules are the company's main product, projected to generate revenue of 335 million yuan in 2024, accounting for 46.88% of total revenue [1] - For the first three quarters of 2025, revenue from Glucosamine Hydrochloride Capsules is expected to reach 345 million yuan, representing 57.85% of total revenue [1] - The other three products have relatively smaller revenue contributions [1] Group 3: Uncertainties and Risks - The final results of the proposed selections remain uncertain, and relevant procurement contracts have yet to be signed [1] - The quantity of selected products is not clearly defined, and production and sales are subject to policy and market environment influences [1]